Results 171 to 180 of about 90,167 (303)

Biologic treatments for psoriasis have different anatomical specificities in residual PASI

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI ...
Martina Burlando   +8 more
wiley   +1 more source

Psoriatic Arthritis and Sarcopenia: A CrossSectional Ultrasonographic Study. [PDF]

open access: yesArch Rheumatol
Doğan Tosun GC   +4 more
europepmc   +1 more source

Decoding the Prescriber: Dermatology Versus Rheumatology Approaches

open access: yes
Australasian Journal of Dermatology, EarlyView.
Nicole Kah Mun Yoong   +2 more
wiley   +1 more source

A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa   +7 more
wiley   +1 more source

What Is the Diagnostic Capacity of Existing Severity Scoring Tools for Nail Psoriasis?

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background It is challenging to distinguish nail psoriasis (NP) from nonspecific nail changes, contributing to heterogeneity in clinical trials. Existing scoring tools for NP are currently used to assess severity after diagnosis is established.
Evi C. C. Rikken   +5 more
wiley   +1 more source

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

open access: yesInternational Journal of Dermatology, EarlyView.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova   +76 more
wiley   +1 more source

Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population. [PDF]

open access: yesDiagnostics (Basel)
Novell G   +11 more
europepmc   +1 more source

PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PSORIATIC ARTHRITIS: ITS ASSOCIATION WITH INFLAMMATION AND SUBCLINICAL ATHEROSCLEROSIS

open access: diamond, 2016
E. I. Markelova   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy